

CITATION REPORT

List of articles citing

Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones

DOI: 10.1097/01.ju.0000081053.97792.da
Journal of Urology, 2003, 170, 887-91.

Source: <https://exaly.com/paper-pdf/35350599/citation-report.pdf>

Version: 2022-10-03

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
116	Tadalafil in the treatment of erectile dysfunction. 2003 , 4, 472-8		13
115	Phosphodiesterase type 5 inhibitors: a biochemical and clinical correlation survey. 2003 , 15 Suppl 5, S13-9		14
114	An update on the PDE-5 inhibitors (PDE-5i). 2003 , 24, S52-8		17
113	Review of tadalafil in the treatment of erectile dysfunction. 2003 , 4, 2049-56		13
112	Emerging oral drugs for erectile dysfunction. 2004 , 9, 179-189		3
111	Review: PDE-5 inhibitors [a] summary. 2004 , 4, 383-386		3
110	Tadalafil: A Comprehensive Update. 2004 , 2, 225-246		
109	Advances in the Treatment of Erectile Dysfunction: A Focus on Tadalafil. 2004 , 17, 239-250		1
108	Erectile dysfunction: management update. 2004 , 170, 1429-37		68
107	Treatment of erectile dysfunction. 2004 , 15, 215-21		7
106	The efficacy and safety of tadalafil: an update. 2004 , 93, 1276-81		153
105	Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles. 2004 , 27, 114-19		49
104	Phosphodiesterase-5 inhibitors: clinical market and basic science comparative studies. 2004 , 5, 451-9		8
103	Exercising current treatments for erectile dysfunction in diabetes: effective, economic and ego-boosting. 2004 , 21, 211-212		
102	Taking diabetes to the heart of the public health debate. 2004 , 21, 212-213		
101	The impact of erectile dysfunction and its treatment with phosphodiesterase type-5 (PDE5) inhibitors in patients with diabetes. 2004 , 21, 225-230		1
100	Erectile dysfunction: etiology, evaluation, and treatment options. 2004 , 88, 387-416, xi		8

99	Erectile dysfunction: evaluation and new treatment options. 2004 , 66, 664-71	28
98	Current World Literature. 2004 , 16, 263-279	
97	Tadalafil: a long-acting PDE5 inhibitor for the management of erectile dysfunction. 2004 , 1, 185-196	
96	Simultaneous determination of sildenafil, vardenafil and tadalafil as forbidden components in natural dietary supplements for male sexual potency by high-performance liquid chromatography-electrospray ionization mass spectrometry. 2005 , 1066, 89-95	93
95	Phosphodiesterase type 5 inhibitors for erectile dysfunction. 2005 , 96, 257-80	148
94	High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients. 2005 , 17, 5-9	49
93	Phosphodiesterase 11 (PDE11) regulation of spermatozoa physiology. 2005 , 17, 216-23	60
92	The therapeutic dilemma: how to use tadalafil. 2005 , 28 Suppl 2, 74-80	33
91	Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction. 2005 , 23, 374-84	26
90	Tadalafil: a clinical update. 2005 , 1, 203-214	2
89	Clinical monograph for drug formulary review: erectile dysfunction agents. 2005 , 11, 151-71	33
88	Phosphodiesterase type 5 inhibitors: molecular pharmacology and interactions with other phosphodiesterases. 2005 , 11, 4047-58	22
87	Tadalafil. 2005 , 85-107	
86	[Management of erectile dysfunction in the cardiac patient]. 2005 , 130, 2899-903	2
85	Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction. 2005 , 2, 239-47	40
84	Oral Pharmacotherapy for Male Sexual Dysfunction. 2005 ,	
83	A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?. 2005 , 65, 1621-50	128
82	Frequently asked questions about tadalafil for treating men with erectile dysfunction. 2005 , 2, 141-157	1

81	Sildenafil citrate inhibits agonist induced contractions in isolated rat seminal vesicles. <i>Journal of Urology</i> , 2006 , 175, 2350-3	1.5	10
80	An overview of the diagnosis and treatment of erectile dysfunction. 2006 , 66, 2339-55		17
79	Semen and sperm reference ranges for men 45 years of age and older. 2006 , 27, 421-8		80
78	Oral Therapy for Erectile Dysfunction. 2006 , 271-286		
77	Efficacy and safety of tadalafil 5, 10, and 20 mg in Japanese men with erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled study. 2006 , 68, 845-51		18
76	. 2006 ,		
75	Phosphodiesterase 11: a brief review of structure, expression and function. 2006 , 18, 501-9		42
74	JNJ-10280205 and JNJ-10287069: Novel PDE5 inhibitors as clinical candidates for erectile dysfunction. 2006 , 18, 477-83		6
73	Sildenafil citrate improves sperm motility but causes a premature acrosome reaction in vitro. 2007 , 87, 1064-70		65
72	Alterations in sperm motility after acute oral administration of sildenafil or tadalafil in young, infertile men. 2007 , 88, 860-5		54
71	Phosphodiesterase type 5 inhibitors: state of the therapeutic class. 2007 , 34, 507-15, vi		22
70	N-Terminal domain of phosphodiesterase-11A4 (PDE11A4) decreases affinity of the catalytic site for substrates and tadalafil, and is involved in oligomerization. 2007 , 46, 10353-64		29
69	Tadalafil as an in vitro sperm motility stimulant. 2007 , 39, 12-5		16
68	Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics. 2007 , 63, 24-35		46
67	Erectile dysfunction and infertility. 2007 , 4, 20-23		4
66	An evaluation of semen characteristics in men 45 years of age or older after daily dosing with tadalafil 20mg: results of a multicenter, randomized, double-blind, placebo-controlled, 9-month study. 2008 , 53, 1058-65		41
65	The effect of aging on spermatogenesis and pregnancy outcomes. 2008 , 35, 331-9, xi		6
64	Daily vardenafil for 6 months has no detrimental effects on semen characteristics or reproductive hormones in men with normal baseline levels. <i>Journal of Urology</i> , 2008 , 179, 1060-5	1.5	38

63	Oral phosphodiesterase-5 inhibitors and sperm functions. 2008 , 20, 530-6	13
62	The type 5 phosphodiesterase inhibitor tadalafil influences salivary cortisol, testosterone, and dehydroepiandrosterone sulphate responses to maximal exercise in healthy men. 2008 , 93, 3510-4	29
61	Tadalafil in the treatment of erectile dysfunction. 2008 , 4, 1315-30	51
60	Sex and the infertile male. 2009 , 27, 186-90	11
59	Is there a role for PDE5 inhibitors in the management of male infertility due to defects in testicular or epididymal function?. 2009 , 15, 3506-20	9
58	Pharmacotherapy for erectile dysfunction. 2010 , 7, 524-40	125
57	Simultaneous determination of yohimbine, sildenafil, vardenafil and tadalafil in dietary supplements using high-performance liquid chromatography-tandem mass spectrometry. 2010 , 33, 2109-14	40
56	Development of an immunoassay for rapid screening of vardenafil and its potential analogues in herbal products based on a group specific monoclonal antibody. 2010 , 658, 197-203	21
55	Effects of phosphodiesterase-5 inhibitors on Leydig cell secretory function in oligoasthenospermic infertile men: a randomized trial. 2010 , 106, 1181-5	33
54	Practical semen analysis: from A to Z. 2010 , 12, 14-20	29
53	PDE5 inhibitors and their applications. 2010 , 17, 2564-87	21
52	Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. 2010 , 19, 1427-37	52
51	Future prospects in the treatment of erectile dysfunction: focus on avanafil. 2011 , 5, 435-43	14
50	Incidence and nature of testicular toxicity findings in pharmaceutical development. 2011 , 92, 511-25	26
49	Phosphodiesterases in endocrine physiology and disease. 2011 , 165, 177-88	23
48	Simultaneous screening and determination of 18 illegal adulterants in herbal medicines and health foods for male sexual potency by ultra-fast liquid chromatography-electrospray ionization tandem mass spectrometry. 2012 , 35, 2847-57	25
47	Tadalafil: in the treatment of signs and symptoms of benign prostatic hyperplasia with or without erectile dysfunction. 2012 , 29, 771-81	7
46	The Role of PDE5 Inhibitors in the Treatment of Testicular Dysfunction. 2012 ,	

45	ADMET considerations for phosphodiesterase-5 inhibitors. 2012 , 8, 1231-45	11
44	Rapid screening of sildenafil and tadalafil adulterated in healthcare products by Micro-Raman spectroscopy. 2012 , 43, 1985-1990	12
43	Open radical retropubic prostatectomy using high anterior release of the levator fascia and constant haptic feedback in bilateral neurovascular bundle preservation plus early postoperative phosphodiesterase type 5 inhibition: a contemporary series. 2012 , 61, 878-84	14
42	Effects of chronic tadalafil use on the testes and sperm parameters of old albino rats. 2012 , 44 Suppl 1, 370-5	7
41	SOP conservative (medical and mechanical) treatment of erectile dysfunction. 2013 , 10, 130-71	112
40	RGO LBL modified biomimetic electrochemical sensor for detection of Sildenafil in herbal sexual health products. 2013 , 42, 287-92	24
39	Daily dosing of PDE5 inhibitors: where does it fit in?. 2013 , 14, 269-78	5
38	History and physical examination. 39-50	
37	Infertility and male sexual dysfunction. 94-103	1
36	Avanafil for erectile dysfunction in elderly and younger adults: differential pharmacology and clinical utility. 2014 , 10, 701-11	11
35	Effect of acute tadalafil on sperm motility and acrosome reaction: in vitro and in vivo studies. 2014 , 46, 417-22	14
34	Men's Sexual Health and Fertility. 2014 ,	7
33	Once-a-day Tadalafil administration improves the spermogram parameters in fertile patients. 2015 , 87, 210-3	11
32	Clinical Management of Male Infertility. 2015 ,	3
31	Adverse effects of common medications on male fertility. 2015 , 12, 401-13	58
30	Pregabalin does not affect sperm production in healthy volunteers: a randomized, double-blind, placebo-controlled, noninferiority study. 2015 , 15, 150-8	8
29	Vasculopathy and pulmonary hypertension in sickle cell disease. 2015 , 308, L314-24	90
28	Histopathologic and Ultrastructural Changes in Seminiferous Tubules of Adult Male Albino Rats Following Daily Administration of Different Doses of Tadalafil. 2016 , 90, 89-96	3

27	The Effect of Oral Phosphodiesterase-5 Inhibitors on Sperm Parameters: A Meta-analysis and Systematic Review. 2017 , 105, 54-61		14
26	Phosphodiesterase Inhibitors (PDE Inhibitors) and Male Reproduction. 2017 , 1034, 29-38		10
25	Chronic Administration of Tadalafil Improves the Symptoms of Patients with Amicrobic MAGI: An Open Study. 2017 , 2017, 3848545		2
24	The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia. 2017 , 6, 295-304		17
23	Pulmonary hypertension in chronic hemolytic anemias: Pathophysiology and treatment. 2018 , 137, 191-200		11
22	Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction. 2018 , 6, 242-252		49
21	Adverse Effects of Drugs on Male Reproduction. 2018 , 221-241		
20	Standardized Semen Analysis and Quality Control Management for Multicenter Male Reproductive Toxicology Clinical Trials. 2018 , 371-386		
19	Medications With Male Reproductive Side Effects. 2018 , 207-216		
18	Effects of a micronutrient supplementation combined with a phosphodiesterase type 5 inhibitor on sperm quantitative and qualitative parameters, percentage of mature spermatozoa and sperm capacity to undergo hyperactivation: A randomised controlled trial. 2018 , 50, e13071		8
17	An update on the drug safety of treating erectile dysfunction. 2019 , 18, 965-975		5
16	Drugs used in prostatic enlargement and lower urinary tract symptoms: unseen and overlooked effects on sexual health. <i>BIRDEM Medical Journal</i> , 2019 , 9, 240-247	0.1	
15	Effect of phosphodiesterase type 5 inhibitors on sperm motility and acrosome reaction: An study. <i>Investigative and Clinical Urology</i> , 2021 , 62, 354-360	1.9	1
14	Male Sexual Dysfunctions in the Infertile Couple-Recommendations From the European Society of Sexual Medicine (ESSM). <i>Sexual Medicine</i> , 2021 , 9, 100377	2.6	3
13	Effect of Phosphodiesterase-5 Inhibitors on the Treatment of Male Infertility: A Systematic Review and Meta-Analysis. <i>World Journal of Men's Health</i> , 2021 , 39, 776-796	6.4	1
12	Effect of Advanced Age on Male Infertility. 2009 , 105-111		1
11	Erectile Dysfunction: Pharmacological Therapy. 2011 , 675-696		1
10	Sexual Problems and Infertility. 2015 , 179-183		1

- 9 Sex and Chronic Physical Illness. **2017**, 479-506 2
- 8 Tadalafil in the treatment of erectile dysfunction; an overview of the clinical evidence. *Clinical Interventions in Aging*, **2006**, 1, 439-49 3.8 9
- 7 Neue Arzneimittel. **2004**, 37-75
- 6 The patient with malignant disease. **2005**, 57-66 1
- 5 Pde11. **2006**,
- 4 Effects of Phosphodiesterase-5 Inhibitors on Testicular and Sperm Function. **2014**, 229-245
- 3 Effect of Exogenous Medications and Anabolic Steroids on Male Reproductive and Sexual Health. **2020**, 455-468 0
- 2 Strategic Therapies for Ejaculatory Disorders and Erectile Dysfunction in the Infertile Man. **2005**, 169-181
- 1 The impact of erectile dysfunction on infertility and its treatment. **2022**, 57-76